|
LIVE WEBINAR: Friday, December 4, 2020, 12:00 PM – 1:30 PM Pacific Time (3:00 PM – 4:30 PM Eastern Time)
Consensus or Controversy? Investigators Discuss Clinical Practice Patterns and Available Research Data Guiding the Management of Chronic Lymphocytic Leukemia (Part 2 of a 4-Part Series)Faculty
Paul M Barr, MD Medical Director, Clinical Trials Office Professor of Medicine James P Wilmot Cancer Institute University of Rochester Medical Center Rochester, New York Matthew S Davids, MD, MMSc Associate Professor of Medicine Harvard Medical School Director of Clinical Research, Division of Lymphoma Dana-Farber Cancer Institute Boston, Massachusetts Kerry Rogers, MD Assistant Professor in the Division of Hematology The Ohio State University Columbus, Ohio Tanya Siddiqi, MD Associate Professor Director, Chronic Lymphocytic Leukemia Program Department of Hematology and Hematopoietic Cell Transplantation City of Hope National Medical Center Duarte, California Stephan Stilgenbauer, MD Department of Internal Medicine I Saarland University Department of Internal Medicine III Ulm University Homburg, Germany Moderator Neil Love, MD Research To Practice Miami, Florida Friday, December 4, 2020 Topics to Be Discussed
Target Audience
CME Credit Form Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Credit Designation Statement Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Content Validation and Disclosures Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr Barr — Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech, a member of the Roche Group, Gilead Sciences Inc, Janssen Biotech Inc, Merck, MorphoSys, Pharmacyclics LLC, an AbbVie Company, Seagen Inc, TG Therapeutics Inc; Contracted Research: AstraZeneca Pharmaceuticals LP; Data and Safety Monitoring Board/Committee: TG Therapeutics Inc. Dr Davids — Advisory Committee: AbbVie Inc, Ascentage Pharma, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech, a member of the Roche Group, Janssen Biotech Inc, Lilly, Pharmacyclics LLC, an AbbVie Company, TG Therapeutics Inc; Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, AstraZeneca Pharmaceuticals LP, BeiGene, Genentech, a member of the Roche Group, Janssen Biotech Inc, Lilly, MEI Pharma Inc, Merck, Novartis, Pharmacyclics LLC, an AbbVie Company, Verastem Inc, Zentalis Pharmaceuticals; Contracted Research: AbbVie Inc, Ascentage Pharma, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, MEI Pharma Inc, Novartis, Pharmacyclics LLC, an AbbVie Company, Surface Oncology, TG Therapeutics Inc, Verastem Inc. Dr Rogers — Consulting Agreements: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, AstraZeneca Pharmaceuticals LP, Pharmacyclics LLC, an AbbVie Company; Contracted Research: AbbVie Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc; Travel: AstraZeneca Pharmaceuticals LP. Dr Siddiqi — Advisory Committee: Celgene Corporation, Juno Therapeutics, a Celgene Company, Kite, A Gilead Company, Pharmacyclics LLC, an AbbVie Company; Data and Safety Monitoring Board/Committee: BeiGene; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company. Dr Stilgenbauer — Advisory Committee, Consulting Agreements, Contracted Research and Speakers Bureau: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Celgene Corporation, F Hoffmann-La Roche Ltd, Gilead Sciences Inc, GlaxoSmithKline, Janssen Biotech Inc, Novartis.MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc. Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose. SupportersThis activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC. |